Not for treating diagnosed medical pigmentation disorders
outcomes vary by medication, duration, and individual factors
Thank you so much Dr
Next, a detailed historical chronology is presented, covering each major GLP-1-based drug: how it was developed, trial results, and its clinical role
Preliminary data published in June 2023 also suggests that GLP-1 drugs 'could modulate crucial pathways in the pathogenesis of inflammatory bowel disease (IBD), such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity' (Arvanitakis, Theocharis, Popovic
Also, always consult with a healthcare provider to tailor these strategies to your needs and ensure the safe and effective use of the medication.